Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
ImpriMed, Inc.
ImpriMed delivers personalized drug response predictions to help veterinarians choose effective treatments for canine lymphoma and leukemia. The company uses proprietary lab testing on live cancer…
ImpriMed, Inc.
ImpriMed delivers personalized drug response predictions to help veterinarians choose effective treatments for canine lymphoma and leukemia. The company uses proprietary lab testing on live cancer…
TL;DR
What they do: AI-driven live-cell drug response predictions for veterinary (canine/feline) blood cancers
Founded: 2017
Headquarters: Palo Alto / Mountain View, California
Customers / reach: Partnered with 250+ veterinary specialists across 40 U.S. states; processed >21,000 canine and feline lymphoma tests
Funding: Total ≈ $34.73M; $23M Series A (Dec 2023) led by SoftBank Ventures Asia
Company Overview
Problem Domain
Precision medicine for blood cancers (veterinary focus with investigational extension to human oncology)
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
8000000
Pre-Series A to commercialize veterinary drug response prediction service
23000000
Series A to expand AI technology and move toward human oncology applications
Investor Signal
“Backed by strategic and institutional investors including SoftBank Ventures Asia, SK Telecom (strategic participation), KDB Silicon Valley, and a syndicate of venture investors”
Founders
What we do
Join the Team
Startup jobs. A lot of them.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,300+
New This Week
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |